RETAIN: Risk-Enabled Therapy After Neoadjuvant Chemo for MIBC
Daniel M. Geynisman, MD, Chief of the Division of Genitourinary Medical Oncology, Fox Chase Cancer Center, explains the results and utility of the RETAIN trial for bladder sparing in patients with MIBC.